news_6

AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients

BEDFORD, Mass.--(BUSINESS WIRE)--$OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies...

news_6

Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio

Agreement is part of Daiichi Sankyo’s five-year mid-term strategy to transform to a structure primarily focused on patented drugs TOKYO...

news_6

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”),...

BIO-key-International-Inc-1-2

PortalGuard Identity & Access Management (IAM) Platform Chosen by Lawrence County, South Dakota for Frictionless Cyber Security & Insurance Compliance

WALL, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer...